Aligos co-founders Leonid Beigelman (L) and Lawrence Blatt

Ali­gos co-founders shoot back at J&J IP com­plaint with one of their own al­leg­ing fraud

This sto­ry goes all the way back to 2014.

In No­vem­ber of 2014, John­son & John­son ac­quired Alios Bio­Phar­ma, an in­fec­tious dis­ease biotech that was co-found­ed by Lawrence Blatt and Leonid Beigel­man.

Fol­low­ing J&J’s 2014 ac­qui­si­tion, Blatt and Beigel­man would be­come em­ploy­ees at J&J’s Janssen arm, with Blatt be­ing the glob­al head of in­fec­tious dis­eases and vac­cines and Beigel­man be­ing Janssen’s VP of med­i­c­i­nal chem­istry. But Blatt and Beigel­man left Janssen in 2017, start­ing Ali­gos one year lat­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.